Cipla completes acquisition of generic businesses in US

The acquisition of InvaGen Pharmaceuticals provides Cipla with about 40 approved ANDAs, 32 marketed products, and 30 pipeline products which are expected to be approved during the next 4 years.

This acquisition is the second landmark acquisition in Cipla’s 80 year history — the first was Cipla Medpro, South Africa. This acquisition will give scale to Cipla’s US business — currently 8% of total revenue as well as providing a launch pad to introduce Cipla’s pipeline of products in respiratory and injectables, among others, in the coming years. Combined with the pipeline of InvaGen products, the overall portfolio will be wide-ranging and will cover chronic therapies like CVS, CNS, respiratory, oncology and diabetes among others.

The acquisition of InvaGen Pharmaceuticals also provides Cipla with about 40 approved ANDAs, 32 marketed products, and 30 pipeline products which are expected to be approved during the next 4 years. In addition, InvaGen has filed five first-to-file products. Dosage forms include immediate release, modified release and extended release tablets and capsules. With a manufacturing footprint of ~350,000 sq ft of GMP area, InvaGen has three units located in Long Island, NY, with a total production capacity of 12 billion tablets and capsules per annum and about 500 employees. With this acquisition, Cipla will have more relevance to wholesale and retail customers.

Commenting on the acquisition, Mr. Umang Vohra, Global Chief Operating Officer, Cipla Limited said: “The acquisition will further strengthen Cipla’s presence in the US pharmaceutical market. InvaGen’s balanced portfolio, robust manufacturing base and strong R&D capabilities will act as lever to expand Cipla’s reach in the US market.”